Drugdocs | Tresiba

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Tresiba

Chemical Name	insulin degludec
Dosage Form	Injection (subcutaneous; 300 units/3 mL, 600 units/3 mL, 1000 units/10 mL)
Drug Class	Hormones
System	Endocrine
Company	Novo
Approval Year	2015

Indication

To improve blood sugar (glucose) control in adults with diabetes mellitus.

Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Tresiba (insulin degludec) Prescribing Information	2019	Novo Nordisk Inc., Plainsboro, NJ

Document Title	Year	Source
CADTH common drug review: clinical review report: insulin degludec (Tresiba).	2017	CADTH

Document Title	Year	Source
Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: A systematic review and meta-analysis.	2019	Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Efficacy and safety of insulin degludec versus insulin glargine: A systematic review and meta-analysis of fifteen clinical trials.	2018	International Journal of Endocrinology